Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster)

Author： McEwan Phil   Peters John R.   Bergenheim Klas   Currie Craig J.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.22, Iss.1, 2006-01, pp. : 121-129

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Development and validation of a cost–utility model for Type 1 diabetes mellitus

By  

DIABETIC MEDICINE, Vol. 32, Iss. 8, 2015-08 ,pp. : 1023-1035

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes

By Palmer Andrew J.   Dinneen Sean   Gavin James R.   Gray Alastair   Herman William H.   Karter Andrew J.  

Current Medical Research and Opinion, Vol. 22, Iss. 5, 2006-05 ,pp. : 861-872

Informa Healthcare

Access to resources Recommend Favorite

Impact of Changes in HbA1c, Lipids and Blood Pressure on Long-term Outcomes in Type 2 Diabetes Patients: An Analysis Using the CORE Diabetes Model

By Palmer Andrew J.   Roze Stéphane   Valentine William J.   Minshall Michael E.   Hayes Clarice   Oglesby Alan   Spinas Giatgen A.  

Current Medical Research and Opinion, Vol. 20, Iss. 1, 2004-08 ,pp. : 53-58

Informa Healthcare

Access to resources Recommend Favorite

Comments and reply on: Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting

By Currie Craig J.   McEwan Phil   Poole Chris   Valentine William J.   Palmer Andrew J.   Lammert Morten   Nicklasson Lars   Foos Volker   Roze Stéphane  

Current Medical Research and Opinion, Vol. 22, Iss. 5, 2006-05 ,pp. : 967-969

Informa Healthcare

Access to resources Recommend Favorite

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes

By Ray Joshua A.   Boye Kristina S.   Yurgin Nicole   Valentine William J.   Roze Stéphane   McKendrick Jan   Tucker Daniel M. D.   Foos Volker   Palmer Andrew J.  

Current Medical Research and Opinion, Vol. 23, Iss. 3, 2007-03 ,pp. : 609-622

Informa Healthcare

Access to resources Recommend Favorite